$TDAC

Translational Development Acquisition Corp.

Translational Development Acquisition is a blank check company formed to identify and combine with one or more businesses through a merger, share exchange, asset acquisition, share purchase, reorganization or similar transaction. It has not completed a business combination and currently focuses on finding and evaluating potential targets, drawing on its management team’s relationships with investors, executives and financial firms. It seeks businesses that are ready to become public and may benefit from additional capital and industry relationships. The company has two officers and does not intend to have full-time employees before completing a business combination. Its potential income sources are not described. Translational Development Acquisition is headquartered in New York, NY.

0
0
1

No SEC Form 4 filings for $TDAC in the last 30 days.

See all $TDAC insider activity →
Low

Translational Development Acquisition 3Q 2026: Net loss ($9.29M) — 10-Q Summary

Translational Development Acquisition reported a net loss of $9.29M for 3Q 2026, compared to a profit of $1.66M a year earlier. The loss was driven by a $11.0M loss on a Subscription Agreement and $548K in administrative costs, partly offset by $800K in fair-value changes and $1.5M in trust-account dividends. The company has no operating revenues. It plans to merge with ProLogium and extended its business combination deadline to November 24, 2026.

ProLogium Technology Co., Ltd.: ProLogium and Translational Development Acquisition Corp. Announce $50 Million Committed Primary Capital Investment to Support Proposed Business Combination

ProLogium and Nasdaq-listed SPAC TDAC said they secured commitments for a $50 million primary capital investment from existing ProLogium shareholders at a pre-money valuation of about $3.8 billion to support their proposed business combination. Proceeds are earmarked for scaling next-generation lithium ceramic batteries and building a Dunkirk, France gigafactory, alongside a French subsidy package up to €1.375 billion.

Translational Development Acquisition Corp. (TDAC): Entry into a Material Definitive Agreement

Translational Development Acquisition Corp. (TDAC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 tm2621361d1_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 Certain information marked with [***] has been excluded from this exhibit because it is not material and is the type that the registrant treats as private or confidential. SUBSCRIPTION AGREEMENT This SUBSCRIPTION AGREEMEN

TDAC sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning TDAC (Translational Development Acquisition Corp.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.

Recent TDAC coverage spans corporate actions, mergers & acquisitions and earnings.

What's driving TDAC

  • The SPAC posted a quarterly loss and disclosed ongoing merger activities, likely pressuring the stock.

    tradingview.com · Nov 16, 2026

  • Financing commitment reduces deal funding risk for TDAC’s SPAC transaction, supporting probability of closing.

    finanznachrichten.de · Jul 28, 2026

  • The 8-K adds deal financing mechanics via a subscription agreement, supporting deal progression but without disclosed economics in the excerpt.

    SEC EDGAR 8-K · Jul 27, 2026

  • The fresh F-4 filing is a procedural but concrete step that can reduce deal uncertainty and keep merger timelines in focus.

    prnewswire.com · Jul 6, 2026

  • Shareholder-approved extension reduces liquidation risk and preserves time to complete a business combination; near-term trading may hinge on extension mechanics and any implied runway.

    SEC EDGAR 8-K · Jun 18, 2026

AlphAI scores every news story that mentions TDAC with an AI model for sentiment and relevance, and aggregates insider trades from Translational Development Acquisition Corp.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $TDAC

Score

Translational Development Acquisition 3Q 2026: Net loss ($9.29M) — 10-Q Summary

Translational Development Acquisition reported a net loss of $9.29M for 3Q 2026, compared to a profit of $1.66M a year earlier. The loss was driven by a $11.0M loss on a Subscription Agreement and $548K in administrative costs, partly offset by $800K in fair-value changes and $1.5M in trust-account dividends. The company has no operating revenues. It plans to merge with ProLogium and extended its business combination deadline to November 24, 2026.

ProLogium Technology Co., Ltd.: ProLogium and Translational Development Acquisition Corp. Announce $50 Million Committed Primary Capital Investment to Support Proposed Business Combination

ProLogium and Nasdaq-listed SPAC TDAC said they secured commitments for a $50 million primary capital investment from existing ProLogium shareholders at a pre-money valuation of about $3.8 billion to support their proposed business combination. Proceeds are earmarked for scaling next-generation lithium ceramic batteries and building a Dunkirk, France gigafactory, alongside a French subsidy package up to €1.375 billion.

$TDACMedOffering· $50M · proposed

Translational Development Acquisition Corp. (TDAC): Entry into a Material Definitive Agreement

Translational Development Acquisition Corp. (TDAC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 tm2621361d1_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 Certain information marked with [***] has been excluded from this exhibit because it is not material and is the type that the registrant treats as private or confidential. SUBSCRIPTION AGREEMENT This SUBSCRIPTION AGREEMEN

$TDACMedShareholder vote

Translational Development Acquisition Corp. (TDAC): Entry into a Material Definitive Agreement

Translational Development Acquisition Corp. (TDAC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false --12-31 0001926599 00-0000000 0001926599 2026-06-17 2026-06-17 0001926599 TDACU:UnitsEachConsistingOfOneClassaOrdinaryShare0.0001ParValueAndOnehalfOfOneRedeemableWarrantMember 2026-06-17 2026-06-17 0001926599 TDACU:ClassaOrdinaryShares0.0001ParValuePerShareMember 2026-06-17

Translational Development Acquisition Corp. (TDAC): Unregistered Sales of Equity Securities

Translational Development Acquisition Corp. (TDAC) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. false 0001926599 00-0000000 0001926599 2026-06-12 2026-06-12 0001926599 TDACU:UnitsEachConsistingOfOneClassaOrdinaryShare0.0001ParValueAndOnehalfOfOneRedeemableWarrantMember 2026-06-12 2026-06-12 0001926599 TDACU:ClassaOrdinaryShares0.0001ParValuePerShareMember 2026-06-12 2026-06

Related tickers